new recommendations from its expert panel on selective COX-2 NSAIDs

Health Canada will now consider new recommendations from its expert panel on selective COX-2 NSAIDs.

This is the first time the public has been asked to sit on an expert advisory panel...along with rheumatologists, internists, etc.

The panel recommends that Celebrex remain on the market...and that Vioxx be allowed to RETURN to the market.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote